PMID- 18516964
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20151119
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 56
IP  - 4
DP  - 2008 Apr
TI  - [New biomarkers for rheumatoid arthritis].
PG  - 297-308
AB  - Rheumatoid factor (RF) has been commonly used as a biomarker of rheumatoid 
      arthritis (RA). It is important to diagnose RA early and to prevent joint 
      destruction before irreversible damage occurs. For this purpose, several new 
      biomarkers, such as anti-cyclic citrullinated peptide antibody (anti-CCP) and 
      matrix metalloproteinase-3 (MMP-3), have become available for both the diagnosis 
      and prognosis of RA. RF showed a tolerable sensitivity of 68.5% for RA, but low 
      specificity of 77.1% for patients with other rheumatic diseases. Anti-agalactosyl 
      IgG antibodies (CARF) showed a slightly higher sensitivity of 73.9%, but 
      specificity as low as that for RF. In contrast, anti-CCP demonstrated high 
      sensitivity of 76.1% and marked specificity of 92.4% for patients with other 
      rheumatic diseases. Anti-CCP was significantly superior to other biomarkers on 
      receiver-operating characteristic curve (ROC) analysis. Moreover, meta-analysis 
      revealed that the pooled sensitivity and specificity were 67% and 95% for 
      anti-CCP, and 69% and 85% for RF, respectively, and that anti-CCP was more 
      specific than RF for diagnosing RA. On the other hand, MMP-3 has been suggested 
      to be a prognostic biomarker as well as an evaluative biomarker for RA. We next 
      examined if the diagnostic accuracy of early RA is improved by combining these 
      biomarkers. The specificity of RF was not as high as anti-CCP but rose to 92% 
      when combined with MMP-3. Thus, we concluded that anti-CCP is superior to other 
      biomarkers in terms of diagnostic accuracy, and that these combined assays are 
      useful in the early diagnosis of RA.
FAU - Hayashi, Nobuhide
AU  - Hayashi N
AD  - Department of Clinical Laboratory, Kobe University Hospital, Kobe 650-0017.
FAU - Nishimura, Kunihiro
AU  - Nishimura K
FAU - Kumagai, Shunichi
AU  - Kumagai S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Arthritis, Rheumatoid/*diagnosis
MH  - Autoantibodies/*blood
MH  - Biomarkers/blood
MH  - Early Diagnosis
MH  - Humans
MH  - Immunoglobulin G
MH  - Matrix Metalloproteinase 3/*blood
MH  - Meta-Analysis as Topic
MH  - Peptides, Cyclic/*immunology
MH  - Prognosis
MH  - Rheumatoid Factor/blood
MH  - Sensitivity and Specificity
RF  - 51
EDAT- 2008/06/04 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/06/04 09:00
PHST- 2008/06/04 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/06/04 09:00 [entrez]
PST - ppublish
SO  - Rinsho Byori. 2008 Apr;56(4):297-308.